Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1978 3
1979 2
1980 16
1981 18
1982 19
1983 37
1984 29
1985 33
1986 44
1987 55
1988 98
1989 138
1990 216
1991 239
1992 223
1993 242
1994 243
1995 306
1996 252
1997 270
1998 298
1999 331
2000 288
2001 441
2002 410
2003 471
2004 454
2005 506
2006 513
2007 534
2008 681
2009 578
2010 611
2011 630
2012 556
2013 599
2014 581
2015 573
2016 551
2017 471
2018 441
2019 437
2020 374
2021 164
Text availability
Article attribute
Article type
Publication date

Search Results

12,833 results
Results by year
Filters applied: . Clear all
Page 1
An overview of the bioactivity of monacolin K / lovastatin.
Xiong Z, Cao X, Wen Q, Chen Z, Cheng Z, Huang X, Zhang Y, Long C, Zhang Y, Huang Z. Xiong Z, et al. Food Chem Toxicol. 2019 Sep;131:110585. doi: 10.1016/j.fct.2019.110585. Epub 2019 Jun 15. Food Chem Toxicol. 2019. PMID: 31207306 Review.
In addition to lowering blood lipid levels, MK also prevents colon cancer, acute myeloid leukemia and neurological disorders such as Parkinson's disease and type I neurofibromatosis. The aim of this manuscript is to comprehensively review the progress in the study of the b …
In addition to lowering blood lipid levels, MK also prevents colon cancer, acute myeloid leukemia and neurological disorders such as Parkins …
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
Tobert JA. Tobert JA. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. doi: 10.1038/nrd1112. Nat Rev Drug Discov. 2003. PMID: 12815379 Review.
One possibility was to reduce cholesterol biosynthesis, and the rate-limiting enzyme in the cholesterol biosynthetic pathway, 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, was a natural target. Here, I describe the discovery and development of lovastatin--the first …
One possibility was to reduce cholesterol biosynthesis, and the rate-limiting enzyme in the cholesterol biosynthetic pathway, 3-hydroxy-3-me …
An overview on the biosynthesis and metabolic regulation of monacolin K/lovastatin.
Zhang Y, Chen Z, Wen Q, Xiong Z, Cao X, Zheng Z, Zhang Y, Huang Z. Zhang Y, et al. Food Funct. 2020 Jul 22;11(7):5738-5748. doi: 10.1039/d0fo00691b. Food Funct. 2020. PMID: 32555902 Free article. Review.
Lovastatin's biosynthetic pathway and gene cluster composition have been studied in depth in Aspergillus terreus. Evidence shows that the MK biosynthetic pathway and gene cluster in Monascus sp. are similar to those of lovastatin in A. terreus. Currently, res
Lovastatin's biosynthetic pathway and gene cluster composition have been studied in depth in Aspergillus terreus. Evidence sho
Lovastatin production: From molecular basis to industrial process optimization.
Mulder KC, Mulinari F, Franco OL, Soares MS, Magalhães BS, Parachin NS. Mulder KC, et al. Biotechnol Adv. 2015 Nov 1;33(6 Pt 1):648-65. doi: 10.1016/j.biotechadv.2015.04.001. Epub 2015 Apr 11. Biotechnol Adv. 2015. PMID: 25868803 Review.
Lovastatin, composed of secondary metabolites produced by filamentous fungi, is the most frequently used drug for hypercholesterolemia treatment due to the fact that lovastatin is a competitive inhibitor of HMG-CoA reductase. ...Studies regarding the lovastatin
Lovastatin, composed of secondary metabolites produced by filamentous fungi, is the most frequently used drug for hypercholesterolemi
[Simvastatin].
Burgmer U, Mohr K. Burgmer U, et al. Dtsch Med Wochenschr. 1996 Jun 7;121(23):769-70. doi: 10.1055/s-0029-1234183. Dtsch Med Wochenschr. 1996. PMID: 8646995 German. No abstract available.
Compactin-a review.
Chakravarti R, Sahai V. Chakravarti R, et al. Appl Microbiol Biotechnol. 2004 Jun;64(5):618-24. doi: 10.1007/s00253-003-1553-7. Epub 2004 Mar 19. Appl Microbiol Biotechnol. 2004. PMID: 15034683 Review.
Biotechnological production and applications of statins.
Barrios-González J, Miranda RU. Barrios-González J, et al. Appl Microbiol Biotechnol. 2010 Jan;85(4):869-83. doi: 10.1007/s00253-009-2239-6. Epub 2009 Oct 10. Appl Microbiol Biotechnol. 2010. PMID: 19820926 Review.
Simvastatin, the second leading statin in the market, is a lovastatin semisynthetic derivative. Lovastatin is mainly produced by Aspergillus terreus strains, and compactin by Penicillium citrinum. ...This lovastatin derivative can be efficiently synthesized f …
Simvastatin, the second leading statin in the market, is a lovastatin semisynthetic derivative. Lovastatin is mainly produced …
Lovastatin for hypercholesterolemia.
Zeller FP, Uvodich KC. Zeller FP, et al. Drug Intell Clin Pharm. 1988 Jul-Aug;22(7-8):542-5. doi: 10.1177/106002808802200703. Drug Intell Clin Pharm. 1988. PMID: 3046888 Review.
One percent of lovastatin patients have discontinued therapy because of intolerable side effects. ...Although the drug should be added to hospital formularies, long-term safety experience and competition from other HMG-CoA reductase inhibitors will determine lovastatin
One percent of lovastatin patients have discontinued therapy because of intolerable side effects. ...Although the drug should be adde …
Lovastatin extended release: a review of its use in the management of hypercholesterolaemia.
Curran MP, Goa KL. Curran MP, et al. Drugs. 2003;63(7):685-99. doi: 10.2165/00003495-200363070-00007. Drugs. 2003. PMID: 12656649 Review.
Lovastatin extended release (ER) provides a new form of delivery for lovastatin, an HMG-CoA reductase inhibitor. ...The tolerability profile of lovastatin ER was similar to that of lovastatin IR. There were no reports of clinically relevant elevations
Lovastatin extended release (ER) provides a new form of delivery for lovastatin, an HMG-CoA reductase inhibitor. ...The tolera
12,833 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page